Citation Impact
Citing Papers
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
2011
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
2016
EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
2010
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3 –Positive Acute Myeloid Leukemia
2017
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma
2015
Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
2014
Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations
2010
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
2012
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
2017
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
2011
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
2017
Cancer statistics, 2023
2023 Standout
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
2016
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas
2012
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
2009
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
Kinase-targeted cancer therapies: progress, challenges and future directions
2018
First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
2016
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution
2024 StandoutNobel
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
2017
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
2014
Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia
2017
Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
2015
<p>Antitumor activity of larotrectinib in tumors harboring <em>NTRK </em>gene fusions: a short review on the current evidence</p>
2019
A view on drug resistance in cancer
2019 StandoutNature
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
2011
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
2017
Molecular mechanisms of epithelial–mesenchymal transition
2014 Standout
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
2015
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
2015
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
2008
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
2014
Understanding and targeting resistance mechanisms in NSCLC
2017
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Lung cancer: New biological insights and recent therapeutic advances
2011
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
2018
Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer
2016
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
Lung cancer: current therapies and new targeted treatments
2016 Standout
The Evolving Landscape of Brain Metastasis
2018
Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
2015
Treating ALK-positive lung cancer—early successes and future challenges
2012
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases
2011
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
2012
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
2013
ErbBs in lung cancer
2008
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
2014
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015
Targeting apoptosis in cancer therapy
2020 Standout
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
2014
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
2014
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib
2018
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
2014
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
2010 Standout
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
2014
Transcriptomic profiling identifies a PU.1 regulatory network in macrophages
2009
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
2016
EMT: 2016
2016 Standout
Hierarchical Maintenance of MLL Myeloid Leukemia Stem Cells Employs a Transcriptional Program Shared with Embryonic Rather Than Adult Stem Cells
2009
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
2012
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Transcriptional control of granulocyte and monocyte development
2007
Getting to the stem of chronic myeloid leukaemia
2008
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
2012
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2017
ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer
2014
The basics of epithelial-mesenchymal transition
2009 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Clonal evolution in cancer
2012 StandoutNature
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Acquired resistance to TKIs in solid tumours: learning from lung cancer
2014
The biology and treatment of EML4-ALK non-small cell lung cancer
2010
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
2017
Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation
2007
The Kruppel‐like factor KLF4 is a critical regulator of monocyte differentiation
2007
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells
2009
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
2014 Standout
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
2011
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
2007 Standout
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 Expression
2014
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
2017
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
2016
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
2009
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Cancer genomics: from discovery science to personalized medicine
2011
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
2009 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Development of Monocytes, Macrophages, and Dendritic Cells
2010 StandoutScience
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification
2012
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
2011
Acute Myeloid Leukemia
2015 Standout
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
2018
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
2015
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
2015
ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells
2014
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non–Small-Cell Lung Cancer
2012
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion‐positive non–small cell lung cancer
2017
Leptomeningeal disease: current diagnostic and therapeutic strategies
2017
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
2016
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
2009
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
2022
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
2015
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Metabolic reprogramming and cancer progression
2020 StandoutScience
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
2013
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
2008
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
2011
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
2015
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients
2014
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
2016
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
2012
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
2015
Works of Daniel B. Costa being referenced
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
2009
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
2018
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
2015
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
2007
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
2010
Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients
2003
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
2013
ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers
2011
Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
2012
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
2015
Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
2012
Acquired Resistance to the ALK Inhibitor Crizotinib in the Absence of an ALK Mutation
2012
BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
2007
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice
2013
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
2014
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
2015
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
2016
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
2012
Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
2006
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
2009
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
2011
Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC).
2017
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
2010
SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
2014
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
2011
Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC).
2013
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
2016
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
2015
A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression.
2015
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
2008
Clinical Activity of Crizotinib in Ros1-Rearranged Non-Small Cell Lung Cancer
2014
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
2011
Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.
2010
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations
2012
Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations
2014
Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis.
2015
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
2011